<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0305210707
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rybelsus
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SEMAGLUTIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C , Protect from light and moisture
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        456.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BJ06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rybelsus<sup>&reg;</sup> contains the active substance semaglutide. It is a medicine that is used to lower blood sugar levels.</p><p>Rybelsus<sup>&reg;</sup> is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p><p>Rybelsus<sup>&reg;</sup> is used to treat type 2 diabetes in adult patients (aged 18 years and older) that cannot be controlled by diet and exercise alone.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rybelsus<sup>&reg;</sup> can be used without other medicines in patients who cannot take metformin (another diabetes medicine).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rybelsus<sup>&reg;</sup> can also be used with other medicines for the treatment of diabetes. These may be medicines taken by mouth or given by injection such as insulin.</p><p>&nbsp;</p><p>It is important that you continue with your diet and exercise plan as agreed with your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>Limitation of Use:</p><p>&nbsp;</p><ul><li>Rybelsus<sup>&reg;</sup> has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rybelsus<sup>&reg;</sup> is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>What is type 2 diabetes?</strong></p><p>Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body makes does not lower your blood sugar the way it should. In some cases, your body can produce too much blood sugar. If your blood sugar increases and remains high over a long period of time, this can lead to harmful effects such as heart problems, kidney disease, eye disorders and poor circulation in your limbs. That is why it is important to keep your blood sugar levels within a normal range.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Rybelsus<sup>&reg;</sup></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to semaglutide or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personal or family history of medullary thyroid carcinoma MTC in patient with Multiple Endocrine Neoplasia syndrome type 2 MEN 2.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Semaglutide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Diabetic ketoacidosis has been reported in insulin-dependent patients whom had rapid discontinuation or dose reduction of insulin when treatment with a GLP-1 receptor agonist is started</p><p>There is no therapeutic experience in patients with congestive heart failure New York Heart Association NYHA class IV and semaglutide is therefore not recommended in these patients Experience with the use of semaglutide in patients with severe renal impairment is limited. Semaglutide is not recommended in patients with end-stage renal disease</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before taking Rybelsus<sup>&reg;</sup>.</p><p>&bull; Risk of Thyroid C-Cell Tumors</p><p>&bull; Use caution in patients with prior anaphylaxis and angioedema history with other GLP-1 receptor agonists. Acute kidney injury and worsening of chronic renal failure, sometimes requiring dialysis, has been reported in patients receiving GLP-1 receptor agonists; Some of these events have been reported in patients without known underlying renal disease. Majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Rybelsus in patients reporting severe adverse gastrointestinal reactions.</p><p>&nbsp;</p><p><strong>Traceability</strong></p><p>In order to improve the traceability of biological medicinal products, record the name and the lot number (included on the outer cartons and blister) of the medicine you are taking and provide this information when reporting any side effects.</p><p>&nbsp;</p><p><strong>General:</strong></p><p>This medicine is not the same as insulin and you should not use it if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have type 1 diabetes (your body does not produce any insulin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you develop diabetic ketoacidosis. This is a complication of diabetes with high blood sugar, breathing difficulty, confusion, excessive thirst, a sweet smell to the breath or a sweet or metallic taste in the mouth.</p><p>If you know that you are due to have surgery where you will be under anesthesia (sleeping), please tell your doctor that you are taking Rybelsus.</p><p><strong>Stomach and gut problems and dehydration</strong></p><p>During treatment with this medicine, you may feel sick (nausea) or be sick (vomiting), or have diarrhoea. These side effects can cause dehydration (loss of fluids). It is important that you drink enough fluids to prevent dehydration. This is especially important if you have kidney problems. Talk to your doctor if you have any questions or concerns.</p><p>&nbsp;</p><p><strong>Severe and on-going stomach pain which could be due to an inflamed pancreas</strong></p><p>If you have severe and on-going pain in the stomach area &ndash; see a doctor straight away as this could be a sign of inflamed pancreas (acute pancreatitis).</p><p>&nbsp;</p><p><strong>Low blood sugar (hypoglycaemia)</strong></p><p>Taking a sulfonylurea medicine or insulin with Rybelsus<sup>&reg;</sup> might increase the risk of getting low blood sugar (hypoglycaemia). See section 4 for the warning signs of low blood sugar levels.</p><p>&nbsp;</p><p>Your doctor may ask you to test your blood sugar levels. This will help to decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar.</p><p>&nbsp;</p><p><strong>Diabetic eye disease (retinopathy)</strong></p><p>Fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disease. If you have diabetic eye disease and get eye problems while taking this medicine, talk to your doctor.</p><p>&nbsp;</p><p><strong>Treatment response</strong></p><p>If the treatment response with semaglutide is lower than expected, this may be due to low absorption caused by variability in absorption and low absolute bioavailability. You should follow the instructions given in section 3 for optimal effect of semaglutide.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>This medicine is not recommended in children and adolescents aged under 18&nbsp;years as the safety and efficacy in this age group have not been established.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Rybelsus<sup>&reg;</sup></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor, pharmacist or nurse if you are using medicines containing any of the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; levothyroxine which is used for thyroid disease. This is because your doctor may need to check your thyroid levels if you are taking Rybelsus<sup>&reg;</sup> together with levothyroxine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin or similar medicines taken by mouth to reduce blood clotting (oral anti-coagulants). You may need frequent blood tests to check how quickly your blood clots.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using insulin, your doctor will tell you how to reduce the dose of insulin and will recommend you to monitor your blood sugar more frequently, in order to avoid hyperglycaemia (high blood sugar) and diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to breakdown glucose because there is not enough insulin).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>This medicine should not be used during pregnancy, as it is not known if it affects your unborn baby. Therefore, use of contraception is recommended while taking this medicine. If you wish to become pregnant, discuss how to change your treatment with your doctor as you should stop using this medicine at least 2 months in advance. If you become pregnant while using this medicine, talk to your doctor straight away, as your treatment will need to be changed.</p><p>&nbsp;</p><p>Do not use this medicine if you are breast-feeding, as it is unknown if it passes into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Rybelsus&reg; is unlikely to affect your ability to drive and use machines.</p><p>&nbsp;</p><p>Some patients may feel dizzy when taking Rybelsus&reg;. If you feel dizzy, be extra careful while driving or using machines. Talk to your doctor for the further information.</p><p>&nbsp;</p><p>If you use this medicine in combination with a sulfonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. Do not drive or use machines if you get any signs of low blood sugar. See section 2, &lsquo;Warning and precautions&rsquo; for information on increased risk of low blood sugar and section 4 for the warning signs of low blood sugar. Talk to your doctor for further information.</p><p>&nbsp;</p><p><strong>Rybelsus<sup>&reg;</sup> contains sodium</strong></p><p>This medicine contains 23&nbsp;mg sodium (main component of cooking/table salt) in each tablet. This is equivalent to 1% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p><strong>Gallbladder problems</strong></p><p>Gallbladder problems have happened in some people who take Rybelsus<sup>&reg;</sup>. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include:</p><ul><li>pain in your upper stomach (abdomen)</li><li>yellowing of skin or eyes (jaundice)</li><li>fever</li><li>clay-colored stools</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is one 3&nbsp;mg tablet once a day for one month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After one month, your doctor will increase your dose to 7&nbsp;mg once a day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may increase your dose to 14&nbsp;mg once a day if your blood sugar is not controlled well enough with a dose of 7&nbsp;mg once a day.</p><p>Your doctor will prescribe the strength that is right for you. Do not change your dose unless your doctor has told you so. It is not recommended to take two 7&nbsp;mg tablets to get the effect of one 14&nbsp;mg tablet, as this has not been studied.</p><p>&nbsp;</p><p><strong>Taking this medicine</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take your Rybelsus<sup>&reg;</sup> tablet on an empty stomach when you first wake up .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow your Rybelsus<sup>&reg;</sup> tablet whole with a sip of water (up to 120&nbsp;ml). Do not split, crush or chew the tablet, as it is not known if it affects absorption of semaglutide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After taking your Rybelsus<sup>&reg;</sup> tablet wait at least 30&nbsp;minutes before having your first meal or drink of the day or taking other oral medicines. Waiting less than 30 minutes lowers the absorption of semaglutide.</p><p>&nbsp;</p><p><strong>If you take more Rybelsus<sup>&reg;</sup></strong><strong> than you should</strong></p><p>If you take more Rybelsus<sup>&reg;</sup> than you should, talk to your doctor straight away. You may get side effects such as feeling sick (nausea).</p><p><em>&nbsp;</em></p><p><strong>If you forget to take Rybelsus<sup>&reg;</sup></strong></p><p>If you forget to take a dose, skip the missed dose and just take your normal dose the next day.</p><p>&nbsp;</p><p><strong>If you stop taking Rybelsus<sup>&reg;</sup></strong></p><p>Do not stop using this medicine without talking to your doctor. If you stop using it, your blood sugar levels may increase.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; complications of diabetic eye disease (retinopathy). You should tell your doctor if you get eye problems, such as changes in vision, during treatment with this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reactions (anaphylactic reactions). You must get immediate medical help and inform your doctor straight away if you get symptoms such as breathing problems, swelling of face and throat, wheezing, fast heartbeat, pale and cold skin, feeling dizzy or weak.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed pancreas (acute pancreatitis) which could cause severe pain in the stomach and back which does not go away. You should see a doctor immediately if you experience such symptoms.</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bowel obstruction. A severe form of constipation with additional symptoms such as stomach ache, bloating, vomiting etc.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylaxis, angioedema, rash, urticaria</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholecystitis, cholelithiasis requiring cholecystectomy</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) &ndash; this usually goes away over time</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea &ndash; this usually goes away over time</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar (hypoglycaemia) when this medicine is used with medicines that contain a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine.</p><p>&nbsp;</p><p>The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking.</p><p>Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar (hypoglycaemia) when this medicine is used with oral diabetes medicine other than sulfonylurea or insulin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upset stomach or indigestion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed stomach (&lsquo;gastritis&rsquo;) &ndash; the signs include stomach ache, feeling sick (nausea) or being sick (vomiting)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reflux or heartburn &ndash; also called &lsquo;gastro-esophageal reflux disease&rsquo;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; less appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gas (flatulence)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of pancreatic enzymes (such as lipase and amylase) shown in blood tests.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gallstones</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast pulse</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions like rash, itching or hives</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a delay in the emptying of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the way food or drink tastes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a delay in the emptying of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the way food or drink tastes.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>Please report adverse drug events to:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after &lsquo;Expiry&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light and moisture. Store below 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Rybelsus<sup>&reg;</sup> contains </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is semaglutide. Each tablet contains 3, 7 or 14&nbsp;mg semaglutide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are salcaprozate sodium, povidone K90, cellulose microcrystalline, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Rybelsus® looks like and contents of the pack
	Rybelsus® 3 mg tablets are white to light yellow and oval shaped (7.5 mm x 13.5 mm). They have ‘3’ on one side and ‘novo’ on the other side.
	Rybelsus® 7 mg tablets are white to light yellow and oval shaped (7.5 mm x 13.5 mm). They have ‘7’ on one side and ‘novo’ on the other side.
	Rybelsus® 14 mg tablets are white to light yellow and oval shaped (7.5 mm x 13.5 mm). They have ‘14’ on one side and ‘novo’ on the other side.
	
	The 3 mg, 7 mg and 14 mg tablets are available in alu/alu blister cards in pack sizes of 10, 30, 60 and 90 tablets.
	
	Not all pack sizes may be marketed in your country.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd</p><p>Denmark</p><p>This is a Medicament</p><p>-&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp; Keep all medicaments out of reach of children.</p><p>&nbsp;</p><p><em>Rybelsus<sup>&reg;</sup></em><em> is a trademark owned by Novo Nordisk A/S, Denmark</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nov/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ريبلسس<sup>&trade;</sup> على &nbsp;المادة الفعالة &quot;سيماجلوتايد&quot; . وهو دواء يُستخدم لخفض مستويات السكر في الدم.</p><p dir="RTL">يوصف ريبلسس<sup>&trade;</sup> كمساعد للنظام الغذائي وممارسة التمارين الرياضية لتحسين السيطرة على نسبة السكر في الدم لدى البالغين المصابين بداء السكري من النوع الثاني.</p><p dir="RTL">يُستخدم ريبلسس<sup>&trade;</sup> لعلاج البالغين (الذين تتراوح أعمارهم بين 18 عامًا وأكبر) المصابين بمرض السكري من النوع 2 الذي لا يُمكِن التحكُّم به عن طريق اتباع نظام غذائي وممارسة التمارين الرياضية فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن استخدام ريبلسس<sup>&trade;</sup> بدون أدوية أخرى في المرضى الذين لا يُمكِنهم تناوُل ميتفورمين (دواء آخر لمرض السكري).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن أيضًا أن يُستَخدَم ريبلسس<sup>&trade;</sup> مع أدوية أخرى لعلاج مرض السكري. قد تكون هذه أدوية يتم تناوُلها عن طريق الفم أو أنسولين يُعطى عن طريق الحَقْن</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم أن تستمر في نظامك الغذائي وخطة &nbsp;التمارين على النحو المتفق عليه مع طبيبك، أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حدود الاستخدام:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يتم دراسة استخدام ريبلسس<sup>&trade;</sup> في المرضى الذين لديهم التهاب بالبنكرياس. يجب الأخذ بعين الاعتبار العلاجات الأخرى المضادة لمرض السكر في المرضى الذين لديهم تاريخ من التهاب البنكرياس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لايجب استخدام ريبلسس في المرضى المصابين بالنوع الأول من داء السكر أو لعلاج المرضى المصابين بالحماض الكيتوني، حيث أن هذا الدواء لن يكون فعَال في مثل هذه الحالات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما المقصود بمرض السكري من النوع 2</strong>؟</p><p dir="RTL">مرض السكري من النوع 2 عبارة عن حالة مرضية لا يستطيع فيها الجسم إنتاج كمية كافية من الإنسولين، ولا يخفِّض فيها الإنسولين الذي ينتجه الجسم نسبة السكر في الدم كما ينبغي. وفي بعض الحالات، يمكن أن ينتج الجسم الكثير من السكر في الدم. وإذا ارتفع مستوى السكر في دمك وظل مرتفعًا لفترة طويلة من الزمن، فقد يؤدي ذلك إلى آثار ضارة، مثل مشكلات بالقلب، ومرض الكلى، واضطرابات العين وضعف الدورة الدموية في الأطراف. ولهذا السبب فإنه من المهم الحفاظ على المعدل الطبيعي لمستويات السكر في الدم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>لا تتناول ريبلسس</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه سيماجلوتايد أو أي من المكونات الأخرى في هذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;في المرضى الذين يشمل تاريخهم الشخصي أو العائلي الإصابة بسرطان الغدة الدرقية النخاعي أو المرضى الذين يعانون من متلازمة الغدد الصماء نيوبلسا النوع الثاني.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب استخدام سيماجلوتايد في المرضى المصابين بالنوع الأول من داء السكر أو لعلاج المرضى المصابين بالحماض الكيتوني. ثبت حدوث الحماض الكيتوني السكري في المرضى المعتمدين على الإنسولين والذين توقفوا عن تناول الإنسولين بسرعة أو قاموا بخفض جرعة الإنسولين عند بدء العلاج باستخدام ناهض مستقبلات جي ال بي 1.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لاتوجد تجربة علاجية لاستخدام هذا الدواء في المرضى الذين لديهم فشل القلب الاحتقاني</p><p dir="RTL">((NYHA class IV&nbsp; ولذلك لا يُوصى باستخدامه في هؤلاء المرضى.</p><p dir="RTL">التجارب محدودة عند استخدام السيماجلوتايد في المرضى الذين لديهم خلل شديد في الكلى.</p><p dir="RTL">لا ينصح باستخدام سيماجلوتايد في المرضى الذين يعانون من مرض الكلى في المراحل النهائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">تحدّث إلى طبيبك، أو الصيدلي أو الممرضة قبل تناول ريبلسس<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خطر الإصابة بسرطان الغدة الدرقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توخى الحذر عند المرضى الذين يعانون من الحساسية المفرطة والوذمة الوعائية السابقة مع ناهضات المستقبلات جي ال بي 1 الأخرى. تم الإبلاغ عن إصابة حادة في الكلى وتفاقم الفشل الكلوي المزمن ، والذي يتطلب أحيانًا غسيل الكلى ، في المرضى الذين يتلقون ناهضات المستقبلات جي ال بي 1 ؛ تم الإبلاغ عن بعض هذه الأحداث في مرضى ليس لديهم مرض كلوي أساسي معروف. حدثت غالبية الأحداث المبلغ عنها في المرضى الذين عانوا من الغثيان والقيء والإسهال أو الجفاف.&nbsp; يجب مراقبة وظائف الكلى عند بدء أو عند زيادة الجرعات لدواء ربيلسس&trade; في المرضى الذين لديهم عن ردود فعل معوية معوية شديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إمكانية التتبع</strong></p><p dir="RTL">لتحسين إمكانية تتبع المنتجات الطبية البيولوجية، سجِّل اسم الدواء الذي تتناوله ورقم التشغيلة (المدرجَين على العبوات الكرتونية الخارجية والشريط) وقدِّم هذه المعلومات عند الإبلاغ عن أي آثار جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات عامة:</strong></p><p dir="RTL">إن هذا الدواء لا يشبه الإنسولين وينبغي عدم استخدامه إذا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بمرض السكري من النوع 1 (لا ينتج جسمك أي إنسولين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من الحماض الكيتوني السكري. فهذا أحد مضاعفات مرض السكري المصحوبة بارتفاع نسبة السكر في الدم، وصعوبة التنفس، والارتباك، والعطش الشديد، والرائحة الحلوة عند التنفس أو الطعم الحلو أو المعدني في الفم.</p><p dir="RTL">ﯾُﺮﺟﻰاستشارة طبيبك إذا كان أي مما سبق ينطبق عليك. أخبر طبيبك أنك تتناول ريبلسس إذا كنت تعلم أنك ستخضع لعملية جراحية حيث ستكون تحت التخدير (النوم)</p><p dir="RTL"><strong>مشكلات المعدة والأمعاء</strong> والجفاف</p><p dir="RTL">أثناء العلاج بهذا الدواء، قد تشعر بتوعك (غثيان) أو تكون توعكًا (تقيؤ)، أو قد تُصاب بإسهال. ويمكن أن تتسبب هذه الآثار الجانبية في الإصابة بالجفاف (فقدان السوائل). ومن المهم أن تشرب كمية كافية من السوائل لمنع الجفاف. ويعد هذا مهمًا بصفة خاصة إذا كنت تعاني من مشكلات في الكلى. تحدّث إلى طبيبك إذا كان لديك أي أسئلة أو مخاوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ألم المعدة الشديد والمستمر الذي قد يكون بسبب التهاب البنكرياس</strong></p><p dir="RTL">إذا كنت تعاني من ألم شديد ومستمر في منطقة المعدة - فراجع الطبيب على الفور لأن ذلك قد يكون علامة على التهاب البنكرياس (التهاب البنكرياس الحاد).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;انخفاض السكر في الدم (نقص سكر الدم)</strong></p><p dir="RTL">قد يزيد تناول دواء السلفونيليوريا أو الإنسولين مع ريبلسس<sup>&trade;</sup> من مخاطرة الإصابة بانخفاض السكر في الدم (هبوط سكر الدم). انظر القسم 4 للتعرف على العلامات التحذيرية لانخفاض مستويات السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يطلب منك طبيبك اختبار مستويات السكر في الدم. وهذا سيساعدك على تحديد ما إذا كان يتعيّن تغيير جرعة السلفونيليوريا أو الإنسولين لتقليل خطر انخفاض السكر في الدم .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أمراض العين المرتبطة بالسكري (اعتلال الشبكية)</strong></p><p dir="RTL">قد &nbsp;يؤدي التحسن السريع في مستوى السكر في الدم إلى تفاقم أمراض العين المرتبطة بالسكري بشكل مؤقت. فإذا كنت مصابًا بأمراض بالعين مرتبطة بالسكري وكنت تعاني من مشكلات في العين أثناء تناول هذا الدواء، فتحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستجابة للعلاج</strong></p><p dir="RTL">إذا كانت الاستجابة للعلاج باستخدام مادة سيماجلوتايد أقل من المتوقع، فقد يكون ذلك بسبب انخفاض الامتصاص الناجم عن تقلبات الامتصاص وانخفاض التوافر الحيوي المطلق. يجب عليك اتباع التعليمات الواردة في القسم 3 لمعرفة التأثير الأمثل لمادة سيماجلوتايد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى بإعطاء هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا لعدم ثبوت سلامته وفعاليته في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وريبلسس</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى أو قد تناولتها مؤخرًا أو قد تتناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وعلى وجه الخصوص، أخبر طبيبك، أو الصيدلي أو الممرضة إذا كنت تستخدم أدوية تحتوي على أيّ مما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليفوثيروكسين الذي يُستخدم لعلاج أمراض الغدة الدرقية. وذلك لأن طبيبك قد يحتاج إلى التحقق من مستويات الغدة الدرقية إذا كنت تتناول ريبلسس<sup>&trade;</sup> مع ليفوثيروكسين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين أو أدوية مماثلة تؤخذ عن طريق الفم لتقليل تخثر الدم (مضادات التخثر الفموية). فقد تحتاج إلى إجراء اختبارات دم متكررة للتحقق من مدى سرعة &nbsp;تخثر الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم الإنسولين، فسيخبرك طبيبك بكيفية تقليل جرعة الإنسولين وسيوصيك بمراقبة مستوى السكر في الدم بشكل متكرر، لتجنب ارتفاع مستوى السكر في الدم والحماض الكيتوني السكري (إحدى مضاعفات مرض السكري التي تحدث عندما يكون الجسم غير قادر على تكسير الجلوكوز لعدم وجود كمية كافية من الإنسولين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو تُرضعين رضاعة طبيعية، أو إذا كنتِ تظنين أنك قد تكونين حاملاً أو كنتِ تخططين للإنجاب، فاسألي طبيبك قبل أخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استخدام هذا الدواء أثناء الحمل، لأنه من غير المعروف ما إذا كان يؤثر على الجنين أم لا. ومن ثمّ، فإنه يوصى باستخدام موانع الحمل أثناء تناول هذا الدواء. إما إذا كنتِ ترغبين في الحمل، فتناقشي مع طبيبك حول كيفية تغيير علاجِك لأنه ينبغي التوقف عن استخدام هذا الدواء قبل شهرين على الأقل. وإذا أصبحتِ حاملاً أثناء استخدام هذا الدواء، فتحدثي إلى طبيبك على الفور، لأنه سيلزم تغيير علاجِك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدمي هذا الدواء إذا كنتِ ترضعين طفلك رضاعة طبيعية، لأنه غير معروف ما إذا كان ينتقل إلى &nbsp;حليب الأم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يتسبب ريبلسس&trade; في التأثير على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يشعر بعض المرضى بالدوار عند أخذ ريبلسس&trade;. إذا شعرت بالدوار، توخ مزيدًا من الحذر عند القيادة أو استخدام الآلات. استشر الطبيب المتابع لك لكي تعرف مزيدًا من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تستخدم هذا الدواء في توليفة مع السلفونيليوريا أو الإنسولين، فقد ينخفض مستوى السكر في دمك (نقص سكر الدم)، ما قد يقلل من قدرتك على التركيز. ومن ثمّ فإنه يجب عدم قيادة المركبات أو استخدام الآلات إذا ظهرت عليك أي علامات لانخفاض مستوى السكر في الدم. راجع القسم 2، &quot;تحذيرات واحتياطات&quot; للحصول على معلومات حول زيادة خطر انخفاض سكر الدم والقسم 4 للاطلاع على العلامات التحذيرية لانخفاض سكر الدم. وتحدّث إلى الطبيب للحصول على مزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل المرارة</strong></p><p dir="RTL">قد یسبب ريبلسس<sup>&trade;</sup> مشاكل في المرارة بما في ذلك حصوات المرارة . اتصل بطبیبك إذا كان لدیك أي من الأعراض التالیة:</p><p dir="RTL">&bull; ألم في الجزء العلوي من معدتك (البطن)</p><p dir="RTL">&bull; حمى</p><p dir="RTL">&bull; اصفرار بشرتك أو عینیك (الیرقان)</p><p dir="RTL">&bull; براز بلون الطین</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ريبلسس</strong><strong><sup>&trade;</sup></strong><strong> يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على 23 ملجم صوديوم (المكون الرئيسي للطهي/ملح الطعام) في كل قرص. وهذا يعادل 1% من الحد الأقصى الموصى به يوميًا من تناول الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا كما أوصاك الطبيب بالضبط. وتحقق من الطبيب أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مقدار الجرعة التي تتناولها</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل الجرعة الأولية في قرص واحد، 3 ملجم، مرة واحدة يوميًا لمدة شهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد مرور شهر، سيزيد الطبيب الجرعة إلى 7 ملجم مرة واحدة يوميًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يزيد الطبيب الجرعة إلى 14 ملجم مرة واحدة يوميًا إذا لم يتم التحكم في نسبة السكر في الدم بشكل جيد بما يكفي في حال تناول 7 ملجم مرة واحدة يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيصف لك الطبيب التركيز المناسب لك. فلا تغيّر الجرعة ما لم يكن قد أخبرك الطبيب بذلك. ولا يُنصح بتناول قرصين 7 ملجم للحصول على تأثير قرص 14 ملجم، لأنه لم تتم دراسة ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول هذا الدواء</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول قرص ريبلسس<sup>&reg;</sup> على معدة فارغة بمجرد أن تستيقظ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابلع قرص ريبلسس<sup>&trade;</sup> كاملاً مع رشفة من الماء (حتى 120 مل). ولا تقسّم القرص، أو تسحقه أو تمضغه، لأنه لا يُعرف ما إذا كان يؤثر على امتصاص مادة سيماجلوتايد أم لا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد تناول قرص ريبلسس<sup>&trade;</sup>، انتظر 30 دقيقة على الأقل قبل تناول وجبتك الأولى أو مشروبك اليومي أو تناوُل أدوية أخرى عن طريق الفم. فالانتظار لمدة أقل من 30 دقيقة يقلل من امتصاص مادة سيماجلوتايد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة من ريبلسس</strong><strong><sup>&trade;</sup></strong><sup> </sup><strong>أكثر مما ينبغي </strong></p><p dir="RTL">في حالة تناول جرعة من ريبلسس<sup>&trade;</sup> أكثر مما ينبغي، تحدث مع الطبيب على الفور. فقد تظهر عليك آثار جانبية، مثل الشعور بالتعب (الغثيان).</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>في حالة نسيان تناول جرعة ريبلسس</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">إذا نسيت تناول جرعة ما، فتخط هذه الجرعة الفائتة وتناول فقط الجرعة المعتادة في اليوم التالي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن تناول ريبلسس</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">لا تتوقف عن استخدام هذا الدواء دون التحدُّث إلى الطبيب. فقد يرتفع مستوى السكر في الدم إذا توقفت عن استعماله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيب، أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، بالرغم من أنها لا تحدث لدى جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى الإبلاغ عن الأعراض الجانبية إلى</p><p dir="RTL">&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:373px"><tbody><tr><td style="width:370px"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية:</p><p dir="RTL">للاتصال بالمركز الموحد للهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">بريد الالكتروني:&nbsp; npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة</strong> (قد تصيب شخصًا واحدًا بحد أقصى من بين كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاعفات أمراض العين المرتبطة بالسكري (اعتلال الشبكية). ينبغي أن تخبر الطبيب إذا كنت تعاني من مشكلات في العين، مثل تغيُّرات في الرؤية، أثناء العلاج بهذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة</strong> (قد تصيب شخصًا واحدًا بحد أقصى من بين كل 1000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة (تفاعلات تأقية). يجب الحصول على مساعدة طبية فورية وإبلاغ الطبيب على الفور إذا ظهرت عليك أعراض مثل مشكلات التنفس، وتورم الوجه والحلق، والأزيز، وسرعة ضربات القلب، وشحوب الجلد وبرودته، والشعور بالدوار أو الضعف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس (التهاب البنكرياس الحاد) الذي يمكن أن يسبب ألمًا شديدًا في المعدة والظهر لا يزول. ينبغي عليك زيارة الطبيب على الفور إذا ظهرت عليك مثل هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقدير معدل التكرار من البيانات المتاحة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء. شكل حاد من الإمساك مصحوب بأعراض إضافية مثل ألم في المعدة، وانتفاخ، وتقيؤ وما إلى ذلك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية، وذمة وعائية، طفح جلدي، أرتكاريا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة، التحصي الصفراوي الذي يتطلب استئصال المرارة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص من بين كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك (الغثيان) - عادةً ما يزول بمرور الوقت</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال - عادةً ما يزول بمرور الوقت</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض السكر في الدم (نقص جلوكوز الدم) عند استخدام هذا الدواء مع أدوية تحتوي على سلفونيليوريا أو إنسولين. قد يقلل الطبيب الجرعة الموصوفة لك من هذه الأدوية قبل البدء في استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر العلامات التحذيرية لانخفاض مستوى السكر في الدم فجأة. ويمكن أن تشمل هذه العلامات: العرق البارد، أو البشرة الباهتة، أو الصداع، أو سرعة ضربات القلب، أو الشعور بالتوعك (الغثيان) أو الجوع الشديد، أو تغيّرات في الرؤية، أو الشعور بالنعاس أو الضعف، أو الشعور بالعصبية، أو القلق أو الارتباك، أو صعوبة التركيز أو الارتجاف.</p><p dir="RTL">&rlm;‫سيخبرك الطبيب بكيفية علاج انخفاض مستوى السكر في الدم وما يجب عليك فعله في حال ملاحظة هذه العلامات التحذيرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تصيب شخصًا واحدًا بحد أقصى من بين كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض السكر في الدم (نقص سكر الدم) عند استخدام هذا الدواء مع دواء يُؤخذ عن طريق الفم لمرض السكري غير السلفونيليوريا أو الإنسولين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوعك (التقيؤ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب المعدة أو عسر الهضم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بالمعدة )التهاب المعدة) - تتضمن علاماتها آلام المعدة، أو الشعور بالتوعك (الغثيان) أو التوعك (القيؤ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتجاع أو حرقة المعدة - وتسمى أيضًا &quot;مرض الارتجاع المعدي المريئي&quot;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غازات البطن (انتفاخ البطن)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات البنكرياس (مثل الليباز والأميليز) الموضحة في اختبارات الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong>(قد تصيب شخصًا واحدًا بحد أقصى من بين كل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصوات مرارية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التجشؤ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة النبض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية مثل الطفح الجلدي، أو الحكة أو الشرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخير في إفراغ المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّر في مذاق الطعام أو الشراب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدّث إلى طبيبك، أو الصيدلي أو الممرضة. ويشمل هذا أي آثار جانبية محتملة غير واردة في هذه النشرة. فبالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على الشريط الفقاعي والعلبة الكرتونية بعد كلمة &quot;Expiry&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزن في العبوة الأصلية لحمايته من الضوء والرطوبة. يُخزن في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات ريبلسس</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل المادة الفعَّالة في سيماجلوتايد. يحتوي كل قرص على 3 أو 7 أو 14 ملجم سيماجلوتايد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى عبارة عن صوديوم سالكابروزات، بوفيدون K90، سليلوز دقيق التبلور، ستيرات مغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل ريبلسس</strong><strong><sup>&trade;</sup></strong><strong> ومحتويات العبوة</strong></p><p dir="RTL">أقراص ريبلسس &trade; بجرعة 3 ملجم عبارة عن أقراص بيضاء إلى صفراء فاتحة بيضاوية الشكل (7.5 ملم &times; 13.5 ملم). مكتوب علي أحد جانبيها رقم &quot;3&quot; وعلى الجانب الآخر كلمة &quot;novo&quot;.</p><p dir="RTL">أقراص ريبلسس&trade; بجرعة 7 ملجم عبارة عن أقراص بيضاء إلى صفراء فاتحة بيضاوية الشكل (7.5 ملم &times; 13.5 ملم). مكتوب علي أحد جانبيها رقم &quot;7&quot; وعلى الجانب الآخر كلمة &quot;novo&quot;.</p><p dir="RTL">أقراص ريبلسس&trade; بجرعة 14 &nbsp;ملجم عبارة عن أقراص بيضاء إلى صفراء فاتحة بيضاوية الشكل (7.5 ملم &times; 13.5 ملم). مكتوب علي أحد جانبيها رقم &quot;14&quot; وعلى الجانب الآخر كلمة &quot;novo&quot;.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">تتوافر الأقراص بتركيز 3 ملجم و7 ملجم و14 ملجم في شرائط فقاعية من الألومنيوم في عبوات تحتوي على 10، و30، و60 و90 قرصًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p dir="RTL">Denmark</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن هذا الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافاً للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن الطبيب والصيدلي هما الخبيران في الدواء وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول أيدي الأطفال.</p><p dir="RTL"><em>ريبلسس</em><em><sup>&trade;</sup></em><em> هي علامة تجارية مملوكة لشركة</em> <em>Novo Nordisk A/S</em><em>،</em> <em>الدنمارك</em></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rybelsus 3 mg tablets
Rybelsus 7 mg tablets
Rybelsus 14 mg tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rybelsus 3 mg tablets

Each tablet contains 3 mg semaglutide*.

Rybelsus 7 mg tablets

Each tablet contains 7 mg semaglutide*.

Rybelsus 14 mg tablets

Each tablet contains 14 mg semaglutide*.

*human glucagon-like peptide-1 (GLP-1) analogue produced in Saccharomyces cerevisiae cells by recombinant DNA technology.

Excipient with known effect

Each tablet, regardless of semaglutide strength, contains 23 mg sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet

Rybelsus 3 mg tablets

White to light yellow, oval shaped tablet (7.5 mm x 13.5 mm) debossed with ‘3’ on one side and ‘novo’ on the other side.

Rybelsus 7 mg tablets

White to light yellow, oval shaped tablet (7.5 mm x 13.5 mm) debossed with ‘7’ on one side and ‘novo’ on the other side.

Rybelsus 14 mg tablets

White to light yellow, oval shaped tablet (7.5 mm x 13.5 mm) debossed with ‘14’ on one side and ‘novo’ on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as monotherapy when metformin is considered inappropriate due to intolerance or contraindications</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with other medicinal products for the treatment of diabetes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rybelsus has not been studied in patient with a history of pancreatitis. Consider other antidiabetics therapies in patients with history of pancreatitis.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rybelsus is not indicated for use in patient with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not effective in these setting.&rdquo;</p><p>&nbsp;</p><p>For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The starting dose of semaglutide is 3&nbsp;mg once daily for one month. After one month, the dose should be increased to a maintenance dose of 7&nbsp;mg once daily. After at least one month with a dose of 7&nbsp;mg once daily, the dose can be increased to a maintenance dose of 14&nbsp;mg once daily to further improve glycaemic control.</p><p>&nbsp;</p><p>The maximum recommended single daily dose of semaglutide is 14&nbsp;mg. Taking two 7&nbsp;mg tablets to achieve the effect of a 14&nbsp;mg dose has not been studied and is therefore not recommended.</p><p>&nbsp;</p><p>For information on switching between oral and subcutaneous (s.c.) semaglutide, see section 5.2.</p><p>&nbsp;</p><p>When semaglutide is used in combination with metformin and/or a sodium-glucose co-transporter-2 inhibitor (SGLT2i) or thiazolidinedione, the current dose of metformin and/or SGLT2i or thiazolidinedione can be continued.</p><p>&nbsp;</p><p>When semaglutide is used in combination with a sulfonylurea or with insulin, a reduction in the dose of sulfonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see section 4.4 and 4.8).</p><p>&nbsp;</p><p>Self-monitoring of blood glucose is not needed in order to adjust the dose of semaglutide. Blood glucose self-monitoring is necessary to adjust the dose of sulfonylurea and insulin, particularly when semaglutide is started and insulin is reduced. A stepwise approach to insulin reduction is recommended.</p><p>&nbsp;</p><p><em>Missed dose</em></p><p>If a dose is missed, the missed dose should be skipped and the next dose should be taken the following day.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is required based on age. Therapeutic experience in patients &ge;75&nbsp;years of age is limited (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required for patients with mild, moderate or severe renal impairment. Experience with the use of semaglutide in patients with severe renal impairment is limited. Semaglutide is not recommended in patients with end-stage renal disease (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required for patients with hepatic impairment. Experience with the use of semaglutide in patients with severe hepatic impairment is limited. Caution should be exercised when treating these patients with semaglutide (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Rybelsus in children and adolescents below 18&nbsp;years have not been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Rybelsus is a tablet for once-daily oral use.</p><p>&nbsp;</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicinal product should be taken on an empty stomach upon waking .</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It should be swallowed whole with a sip of water (up to half a glass of water equivalent to 120&nbsp;ml). Tablets should not be split, crushed or chewed, as it is not known whether this impacts absorption of semaglutide.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients should wait at least 30&nbsp;minutes before eating or drinking or taking other oral medicinal products. Waiting less than 30&nbsp;minutes decreases the absorption of semaglutide (see sections 4.5 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
 • “Personal or family history of medullary thyroid carcinoma MTC in patient with Multiple Endocrine Neoplasia syndrome type 2 MEN 2.”
 • Semaglutide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Diabetic ketoacidosis has been reported in insulin-dependent patients whom had rapid discontinuation or dose reduction of insulin when treatment with a GLP-1 receptor agonist is started
 • There is no therapeutic experience in patients with congestive heart failure New York Heart Association NYHA class IV and semaglutide is therefore not recommended in these patients Experience with the use of semaglutide in patients with severe renal impairment is limited. Semaglutide is not recommended in patients with end-stage renal disease. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>General</u></p><p>&nbsp;</p><p>Semaglutide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Diabetic ketoacidosis has been reported in insulin-dependent patients whom had rapid discontinuation or dose reduction of insulin when treatment with a GLP-1 receptor agonist is started (see section 4.2).</p><p>&nbsp;</p><p>There is no therapeutic experience in patients with congestive heart failure New York Heart Association (NYHA) class IV and semaglutide is therefore not recommended in these patients.</p><p>&nbsp;</p><p>There is no therapeutic experience with semaglutide in patients with bariatric surgery.</p><p><u>Aspiration in association with general anaesthesia or deep sedation</u></p><p><u>&nbsp;</u></p><p>Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists</p><p>undergoing general anaesthesia or deep sedation. Therefore, the increased risk of residual gastric</p><p>content due to delayed gastric emptying (see section 4.8) should be considered prior to performing</p><p>procedures with general anaesthesia or deep sedation.</p><p><strong>&nbsp;</strong></p><p><u>Gastrointestinal effects and dehydration</u></p><p><u>&nbsp;</u></p><p>Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions that can cause dehydration, which in rare cases can lead to a deterioration of renal function (see section 4.8). Patients treated with semaglutide should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.</p><p>&nbsp;</p><p><u>Acute pancreatitis</u></p><p><u>&nbsp;</u></p><p>Acute pancreatitis has been observed with the use of GLP-1 receptor agonists. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, semaglutide should be discontinued; if confirmed, semaglutide should not be restarted. Caution should be exercised in patients with a history of pancreatitis.</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p><u>&nbsp;</u></p><p>Patients treated with semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia (see section 4.8). The risk of hypoglycaemia can be lowered by reducing the dose of sulfonylurea or insulin when initiating treatment with semaglutide (see section 4.2).</p><p>&nbsp;</p><p><u>Diabetic retinopathy</u></p><p><u>&nbsp;</u></p><p>In patients with diabetic retinopathy treated with insulin and s.c. semaglutide, an increased risk of developing diabetic retinopathy complications has been observed, a risk that cannot be excluded for orally administered semaglutide (see data in section 4.8). Caution should be exercised when using semaglutide in patients with diabetic retinopathy. These patients should be monitored closely and treated according to clinical guidelines. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, but other mechanisms cannot be excluded. Long-term glycaemic control decreases the risk of diabetic retinopathy.</p><p>&nbsp;</p><p><u>Treatment response</u></p><p>&nbsp;</p><p>Compliance with the dosing regimen is recommended for optimal effect of semaglutide. If the treatment response with semaglutide is lower than expected, the treating physician should be aware that the absorption of semaglutide is highly variable and may be minimal (2-4% of patients will not have any exposure), and that the absolute bioavailability of semaglutide is low.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains 23&nbsp;mg sodium per tablet, equivalent to 1% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p><p>&nbsp;</p><p>&bull; Risk of Thyroid C-Cell Tumors</p><p><u>&nbsp;</u></p><p>&nbsp;&bull; &ldquo;Use caution in patients with prior anaphylaxis and angioedema history with other GLP-1 receptor agonists.&rdquo; &ldquo;Acute kidney injury and worsening of chronic renal failure, sometimes requiring dialysis, has been reported in patients receiving GLP-1 receptor agonists; Some of these events have been reported in patients without known underlying renal disease. Majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Rybelsus in patients reporting severe adverse gastrointestinal reactions. PILs: The submitted PILs require the following amendments: Kindly amend PILs to reflect changes requested on the SPC.</p><p>&nbsp;</p><p><u>Acute Gallbladder Disease</u></p><p>Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1% of patients treated with RYBELSUS 7 mg. Cholelithiasis was not reported in RYBELSUS 14 mg or placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Semaglutide delays gastric emptying which may influence the absorption of other oral medicinal products.</p><p>&nbsp;</p><p><u>Effects of semaglutide on other medicinal products</u></p><p><u>&nbsp;</u></p><p><em>Thyroxine</em></p><p>Total exposure (AUC) of thyroxine (adjusted for endogenous levels) was increased by 33% following administration of a single dose of levothyroxine. Maximum exposure (C<sub>max</sub>) was unchanged. Monitoring of thyroid parameters should be considered when treating patients with semaglutide at the same time as levothyroxine.</p><p>&nbsp;</p><p><em>Warfarin and other coumarin derivatives</em></p><p>Semaglutide did not change the AUC or C<sub>max </sub>of R- and S-warfarin following a single dose of warfarin, and the pharmacodynamic effects of warfarin as measured by the international normalised ratio (INR) were not affected in a clinically relevant manner. However,cases of decreased INR have been reported during concomitant use of acenocoumarol and semaglutide. Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.</p><p>&nbsp;</p><p><em>Rosuvastatin</em></p><p>AUC of rosuvastatin was increased by 41% [90% CI: 24;&nbsp;60] when co-administered with semaglutide. Based on the wide therapeutic index of rosuvastatin the magnitude of changes in the exposure is not considered clinically relevant.</p><p>&nbsp;</p><p><em>Digoxin, oral contraceptives, metformin, furosemide</em></p><p>No clinically relevant change in AUC or C<sub>max</sub> of digoxin, oral contraceptives (containing ethinylestradiol and levonorgestrel), metformin or furosemide was observed when concurrently administered with semaglutide.</p><p>&nbsp;</p><p>Interactions with medicinal products with very low bioavailability (F: 1%) have not been evaluated.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on semaglutide</u></p><p><u>&nbsp;</u></p><p><em>Omeprazole</em></p><p>No clinically relevant change in AUC or C<sub>max </sub>of semaglutide was observed when taken with omeprazole.</p><p>&nbsp;</p><p>In a trial investigating the pharmacokinetics of semaglutide co-administered with five other tablets, the AUC of semaglutide decreased by 34% and C<sub>max</sub> by 32%. This suggests that the presence of multiple tablets in the stomach influences the absorption of semaglutide if co-administered at the same time. After administering semaglutide, the patients should wait 30 minutes before taking other oral medicinal products (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential are recommended to use contraception when treated with semaglutide.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). There are limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued. Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life (see section 5.2).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>In lactating rats, semaglutide, salcaprozate sodium and/or its metabolites were excreted in milk. As a risk to a breast-fed child cannot be excluded, Rybelsus should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effect of semaglutide on fertility in humans is unknown. Semaglutide did not affect male fertility in rats. In female rats, an increase in oestrous length and a small reduction in number of ovulations were observed at doses associated with maternal body weight loss (see section 5.3).</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Semaglutide has no or negligible influence on the ability to drive or use machines. However, dizziness can be experienced mainly during dose escalation. Driving or use of machines should be done cautiously if dizziness occurs.</p><p>&nbsp;</p><p>When it is used in combination with a sulfonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>In 10 phase 3a trials, 5,707 patients were exposed to semaglutide alone or in combination with other glucose-lowering medicinal products. The duration of the treatment ranged from 26&nbsp;weeks to 78&nbsp;weeks. The most frequently reported adverse reactions in clinical trials were gastrointestinal disorders, including nausea (very common), diarrhoea (very common) and vomiting (common).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>Table 1 lists adverse reactions identified in phase 3 trials (further described in section 5.1) and post marketing reports in patients with type 2 diabetes mellitus. The frequencies of the adverse reactions (except diabetic retinopathy complications, see footnote in Table 1) are based on a pool of the phase 3a trials excluding the cardiovascular outcomes trial.</p><p>&nbsp;</p><p>The reactions are listed below by system organ class and absolute frequency. Frequencies are defined as: very common: (&ge;1/10); common: (&ge;1/100 to &lt;1/10); uncommon: (&ge;1/1,000 to &lt;1/100); rare: (&ge;1/10,000 to &lt;1/1,000) very rare: (&lt;1/10,000). and not known (cannot be estimated from the available data).Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table <!--[if supportFields]><span lang=EN-GB style='font-size:
12.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>SEQ Table \* ARABIC <span style='mso-element:
field-separator'></span></span><![endif]-->1<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--> Frequency of adverse reactions of oral semaglutide</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>MedDRA system organ class</strong></p></td><td><p><strong>Very common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Not Known</strong></p></td></tr><tr><td><p><strong>Immune system disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hypersensitivity<sup>c</sup></p></td><td><p>Anaphylactic reaction</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders </strong></p></td><td><p>Hypoglycaemia when used with insulin or sulfonylurea<sup>a</sup></p></td><td><p>Hypoglycaemia when used with other oral antidiabetic products<sup>a</sup></p><p>Decreased appetite</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Eye disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>Diabetic retinopathy complications<sup>b</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Cardiac disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Increased heart rate</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Gastrointestinal disorders </strong></p></td><td><p>Nausea</p><p>Diarrhoea</p></td><td><p>Vomiting</p><p>Abdominal pain</p><p>Abdominal distension</p><p>Constipation</p><p>Dyspepsia</p><p>Gastritis</p><p>Gastro-oesophageal reflux disease</p><p>Flatulence</p></td><td><p>Eructation</p><p>Delayed gastric emptying</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>Acute pancreatitis</p></td><td><p>Intestinal</p><p>obstruction<sup>d</sup></p></td></tr><tr><td><p><strong>Hepatobiliary disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Cholecystitis, Cholelithiasis requiring cholecystectomy</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>General disorders and administration site conditions </strong></p></td><td><p>&nbsp;</p></td><td><p>Fatigue</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p>&nbsp;</p></td><td><p>Increased lipase</p><p>Increased amylase</p></td><td><p>Weight decreased</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>Dizziness</p></td><td><p>Dysgeusia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>a)</sup> Hypoglycaemia defined as blood glucose &lt;3.0&nbsp;mmol/L or &lt;54&nbsp;mg/dL.</p><p><sup>b)</sup> Diabetic retinopathy complications is a composite of retinal photocoagulation, treatment with intravitreal agents, vitreous haemorrhage and diabetes-related blindness (uncommon). Frequency is based on the cardiovascular outcomes trial with s.c. semaglutide, but it cannot be excluded that the risk of diabetic retinopathy complications identified also applies to Rybelsus.</p><p><sup>c) </sup>Grouped term covering also adverse events related to hypersensitivity such as rash and urticaria.</p><p>d) From post-marketing reports.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Hypoglycaemia</em></p><p>Severe hypoglycaemia was primarily observed when semaglutide was used with a sulfonylurea (&lt;0.1% of subjects, &lt;0.001&nbsp;events/patient year) or insulin (1.1% of subjects, 0.013&nbsp;events/patient year). Few episodes (0.1% of subjects, 0.001&nbsp;events/patient year) were observed with semaglutide in combination with oral antidiabetics other than sulfonylurea.</p><p>&nbsp;</p><p><em>Gastrointestinal adverse reactions</em></p><p>Nausea occurred in 15%, diarrhoea in 10%, and vomiting in 7% of patients when treated with semaglutide. Most events were mild to moderate in severity and of short duration. The events led to treatment discontinuation in 4% of subjects. The events were most frequently reported during the first months on treatment.</p><p>&nbsp;</p><p>Acute pancreatitis confirmed by adjudication has been reported in phase 3a trials, semaglutide (&lt;0.1%) and comparator (0.2%). In the cardiovascular outcomes trial the frequency of acute pancreatitis confirmed by adjudication was 0.1% for semaglutide and 0.2% for placebo (see section 4.4.)</p><p>&nbsp;</p><p><em>Diabetic retinopathy complications</em></p><p>A 2-year clinical trial with s.c. semaglutide investigated 3,297 patients with type 2 diabetes, with high cardiovascular risk, long duration of diabetes and poorly controlled blood glucose. In this trial, adjudicated events of diabetic retinopathy complications occurred in more patients treated with s.c. semaglutide (3.0%) compared to placebo (1.8%). This was observed in insulin-treated patients with known diabetic retinopathy. The treatment difference appeared early and persisted throughout the trial. Systematic evaluation of diabetic retinopathy complication was only performed in the cardiovascular outcomes trial with s.c. semaglutide. In clinical trials with Rybelsus of up to 18&nbsp;months duration involving 6,352 patients with type 2 diabetes, adverse events related to diabetic retinopathy were reported in similar proportions in subjects treated with semaglutide (4.2%) and comparators (3.8%).</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>Consistent with the potential immunogenic properties of medicinal products containing proteins or peptides, patients may develop antibodies following treatment with semaglutide. The proportion of subjects tested positive for anti-semaglutide antibodies at any time point after baseline was low (0.5%) and no subjects had neutralising anti-semaglutide antibodies or anti-semaglutide antibodies with neutralising effect on endogenous GLP-1 at end-of-trial.</p><p>&nbsp;</p><p><em>Heart rate increase</em></p><p>Increased heart rate has been observed with GLP-1 receptor agonists. In the phase 3a trials, mean changes of 0 to 4 beats per minute (bpm) from a baseline of 69 to 76 were observed in patients treated with Rybelsus.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Post marketing experince:</em></p><p>Ileus</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of overdose with semaglutide in clinical studies may be associated with gastrointestinal disorders. In the event of overdose, appropriate supportive treatment should be initiated according to the patient&rsquo;s clinical signs and symptoms. A prolonged period of observation and treatment of the symptoms may be necessary, taking into account the long half-life of semaglutide of approximately 1 week (see section 5.2). There is no specific antidote for overdose with semaglutide.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, Glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ06</p><p>&nbsp;</p><p>Mechanism of action</p><p>&nbsp;</p><p>Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.</p><p>&nbsp;</p><p>GLP-1 is a physiological hormone that has multiple actions in glucose and appetite regulation, and in the cardiovascular system. The glucose and appetite effects are specifically mediated via GLP-1 receptors in the pancreas and the brain.</p><p>&nbsp;</p><p>Semaglutide reduces blood glucose in a glucose-dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. During hypoglycaemia, semaglutide diminishes insulin secretion and does not impair glucagon secretion. The mechanism of semaglutide is independent of the route of administration.</p><p>&nbsp;</p><p>Semaglutide reduces body weight and body fat mass through lowered energy intake, involving an overall reduced appetite. In addition, semaglutide reduces the preference for high fat foods.</p><p>&nbsp;</p><p>GLP-1 receptors are expressed in the heart, vasculature, immune system and kidneys. Semaglutide has a beneficial effect on plasma lipids, lowers systolic blood pressure and reduces inflammation in clinical studies. In animal studies, semaglutide attenuates the development of atherosclerosis by preventing aortic plaque progression and reducing inflammation in the plaque.&nbsp;</p><p>&nbsp;</p><p>Pharmacodynamic effects</p><p>&nbsp;</p><p>The pharmacodynamic evaluations described below were performed with orally administered semaglutide after 12 weeks of treatment.</p><p>&nbsp;</p><p><em><u>Fasting and postprandial glucose</u> </em></p><p>Semaglutide reduces fasting and postprandial glucose concentrations. In patients with type 2 diabetes, treatment with semaglutide resulted in a relative reduction compared to placebo of 22% [13; 30] for fasting glucose and 29% [19; 37] for postprandial glucose.</p><p>&nbsp;</p><p><em><u>Glucagon secretion</u> </em></p><p>Semaglutide lowers the postprandial glucagon concentrations. In patients with type 2 diabetes, semaglutide resulted in the following relative reductions in glucagon compared to placebo: postprandial glucagon response of 29% [15; 41].</p><p><em><u>Gastric emptying</u> </em></p><p>Semaglutide causes a minor delay in early postprandial gastric emptying, with paracetamol exposure (AUC<sub>0-1h</sub>) 31% [13; 46] lower in the first hour after the meal,<sub> </sub>thereby reducing the rate at which glucose appears in the circulation postprandially.</p><p>&nbsp;</p><p><em><u>Fasting and postprandial lipids</u> </em></p><p>Semaglutide compared to placebo lowered fasting triglyceride and very-low-density lipoproteins (VLDL) cholesterol concentrations by 19% [8; 28] and 20% [5; 33], respectively. The postprandial triglyceride and VLDL cholesterol response to a high fat meal was reduced by 24% [9; 36] and 21% [7; 32], respectively. ApoB48 was reduced both in fasting and postprandial state by 25% [2; 42] and 30% [15; 43], respectively.</p><p>&nbsp;</p><p>Clinical efficacy and safety</p><p>&nbsp;</p><p>The efficacy and safety of Rybelsus have been evaluated in eight global randomised controlled phase 3a trials. In seven trials, the primary objective was the assessment of the glycaemic efficacy; in one trial, the primary objective was the assessment of cardiovascular outcomes.</p><p>&nbsp;</p><p>The trials included 8,842 randomised patients with type 2 diabetes (5,169 treated with semaglutide), including 1,165 patients with moderate renal impairment. Patients had an average age of 61 years (range 18 to 92 years), with 40% of patients &ge; 65 years of age and 8% &ge; 75 years of age. The efficacy of semaglutide was compared with placebo or active controls (sitagliptin, empagliflozin and liraglutide).&nbsp;</p><p>&nbsp;</p><p>The efficacy of semaglutide was not impacted by baseline age, gender, race, ethnicity, body weight, BMI, diabetes duration, upper gastrointestinal disease and level of renal function.</p><p>&nbsp;</p><p><em><u>PIONEER 1 &ndash; Monotherapy</u> </em></p><p>In a 26-week double-blind trial, 703 patients with type 2 diabetes inadequately controlled with diet and exercise were randomised to semaglutide 3 mg, semaglutide 7 mg, semaglutide 14 mg or placebo once daily.</p><p>&nbsp;</p><p>Table 2 Results of a 26-week monotherapy trial comparing semaglutide with placebo (PIONEER 1) &nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Semaglutide 7 mg</strong></p></td><td><p><strong>Semaglutide</strong><strong> </strong><strong>14 mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>175</p></td><td><p>175</p></td><td><p>178</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>8.0</p></td><td><p>8.0</p></td><td><p>7.9</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.2</p></td><td><p>&minus;1.4</p></td><td><p>&minus;0.3</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.9 [&minus;1.1; &minus;0.6]*</p></td><td><p>&minus;1.1 [&minus;1.3; &minus;0.9]*</p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>69<sup>&sect;</sup></p></td><td><p>77<sup>&sect;</sup></p></td><td><p>31</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>9.0</p></td><td><p>8.8</p></td><td><p>8.9</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.5</p></td><td><p>&minus;1.8</p></td><td><p>&minus;0.2</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.4 [&minus;1.9; &minus;0.8]<sup>&sect;</sup></p></td><td><p>&minus;1.6 [&minus;2.1; &minus;1.2]<sup>&sect;</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>89.0</p></td><td><p>88.1</p></td><td><p>88.6</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;2.3</p></td><td><p>&minus;3.7</p></td><td><p>&minus;1.4</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.9 [&minus;1.9; 0.1]</p></td><td><p>&minus;2.3 [&minus;3.1; &minus;1.5]*</p></td><td><p>-</p></td></tr></tbody></table><p><sup>1</sup> Irrespective of treatment discontinuation or initiation of rescue medication (pattern mixture model using multiple imputation).<sup> * </sup>p&lt;0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. <sup>&sect;</sup> p&lt;0.05, not controlled for multiplicity; for &lsquo;Patients achieving HbA<sub>1c</sub> &lt;7.0%&rsquo;, the p-value is for the odds ratio.</p><p>&nbsp;</p><p><em><u>PIONEER 2 &ndash; Semaglutide vs. empagliflozin, both in combination with metformin</u> </em></p><p>In a 52-week open-label trial, 822 patients with type 2 diabetes were randomised to semaglutide 14 mg once daily or empagliflozin 25 mg once daily, both in combination with metformin.</p><p>Table 3 Results of a 52-week trial comparing semaglutide with empagliflozin (PIONEER 2)&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:539px"><tbody><tr><td style="width:244px"><p>&nbsp;</p></td><td style="width:118px"><p><strong>Semaglutide 14 mg</strong></p></td><td style="width:174px"><p><strong>Empagliflozin 25 mg</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:538px"><tbody><tr><td><p>Full analysis set (N)</p></td><td><p>411</p></td><td style="width:177px"><p>410</p></td></tr><tr><td><p><strong>Week 26</strong></p></td><td><p>&nbsp;</p></td><td style="width:177px"><p>&nbsp;</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td style="width:177px"><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>8.1</p></td><td style="width:177px"><p>8.1</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.3</p></td><td style="width:177px"><p>&minus;0.9</p></td></tr><tr><td><p>Difference from empagliflozin<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.4 [&minus;0.6; &minus;0.3]*</p></td><td style="width:177px"><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>67<sup>&sect;</sup></p></td><td style="width:177px"><p>40</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td style="width:177px"><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>9.5</p></td><td style="width:177px"><p>9.7</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;2.0</p></td><td style="width:177px"><p>&minus;2.0</p></td></tr><tr><td><p>Difference from empagliflozin<sup>1</sup> [95% CI]</p></td><td><p>0.0 [&minus;0.2; 0.3]</p></td><td style="width:177px"><p>-</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td style="width:177px"><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>91.9</p></td><td style="width:177px"><p>91.3</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;3.8</p></td><td style="width:177px"><p>&minus;3.7</p></td></tr><tr><td><p>Difference from empagliflozin<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.1 [&minus;0.7; 0.5]</p></td><td style="width:177px"><p>-</p></td></tr><tr><td><p><strong>Week 52</strong></p></td><td><p>&nbsp;</p></td><td style="width:177px"><p>&nbsp;</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td style="width:177px"><p>&nbsp;</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.3</p></td><td style="width:177px"><p>&minus;0.9</p></td></tr><tr><td><p>Difference from empagliflozin<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.4 [&minus;0.5; &minus;0.3]<sup>&sect;</sup></p></td><td style="width:177px"><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>66<sup>&sect;</sup></p></td><td style="width:177px"><p>43</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td style="width:177px"><p>&nbsp;</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;3.8</p></td><td style="width:177px"><p>&minus;3.6</p></td></tr><tr><td><p>Difference from empagliflozin<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.2 [&minus;0.9; 0.5]</p></td><td style="width:177px"><p>-</p></td></tr></tbody></table><p><sup>1</sup> Irrespective of treatment discontinuation or initiaton of rescue medicaton (pattern mixture model using multiple imputation). <sup>* </sup>p&lt;0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. <sup>&sect;</sup> p&lt;0.05, not controlled for multiplicity; for &lsquo;Patients achieving HbA<sub>1c</sub> &lt;7.0%&rsquo;, the p-value is for the odds ratio.</p><p>&nbsp;</p><p><em><u>PIONEER 3 &ndash; Semaglutide vs. sitagliptin, both in combination with metformin or metformin with</u> <u>sulfonylurea</u> </em></p><p>In a 78-week, double-blind, double-dummy trial, 1,864 patients with type 2 diabetes were randomised to semaglutide 3 mg, semaglutide 7 mg, semaglutide 14 mg or sitagliptin 100 mg once daily, all in combination with metformin alone or metformin and sulfonylurea. Reductions in HbA<sub>1c </sub>and body weight were sustained throughout the trial duration of 78 weeks.</p><p>Table 4 Results of a 78-week trial comparing semaglutide with sitagliptin (PIONEER 3)&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Semaglutide 7 mg</strong></p></td><td><p><strong>Semaglutide</strong><strong> </strong><strong>14 mg</strong></p></td><td><p><strong>Sitagliptin</strong><strong> </strong><strong>100 mg</strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>465</p></td><td><p>465</p></td><td><p>467</p></td></tr><tr><td><p><strong>Week 26</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>8.4</p></td><td><p>8.3</p></td><td><p>8.3</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.0</p></td><td><p>&minus;1.3</p></td><td><p>&minus;0.8</p></td></tr><tr><td><p>Difference from sitagliptin<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.3 [&minus;0.4; &minus;0.1]<sup>*</sup></p></td><td><p>&minus;0.5 [&minus;0.6; &minus;0.4]<sup>*</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>44<sup>&sect;</sup></p></td><td><p>56<sup>&sect;</sup></p></td><td><p>32</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>9.4</p></td><td><p>9.3</p></td><td><p>9.5</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.2</p></td><td><p>&minus;1.7</p></td><td><p>&minus;0.9</p></td></tr><tr><td><p>Difference from sitagliptin<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.3 [&minus;0.6; 0.0]<sup>&sect;</sup></p></td><td><p>&minus;0.8 [&minus;1.1; &minus;0.5]<sup>&sect;</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>91.3</p></td><td><p>91.2</p></td><td><p>90.9</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;2.2</p></td><td><p>&minus;3.1</p></td><td><p>&minus;0.6</p></td></tr><tr><td><p>Difference from sitagliptin<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.6 [&minus;2.0; &minus;1.1]<sup>*</sup></p></td><td><p>&minus;2.5 [&minus;3.0; &minus;2.0]<sup>*</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Week 78</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td><p>Change from baseline<sup>1</sup></p></td><td style="width:120px"><p>&minus;0.8</p></td><td style="width:127px"><p>&minus;1.1</p></td><td style="width:123px"><p>&minus;0.7</p></td></tr><tr><td><p>Difference from sitagliptin<sup>1</sup> [95% CI]</p></td><td style="width:120px"><p>&minus;0.1 [&minus;0.3; 0.0]</p></td><td style="width:127px"><p>&minus;0.4 [&minus;0.6; &minus;0.3]<sup>&sect;</sup></p></td><td style="width:123px"><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td style="width:120px"><p>39<sup>&sect;</sup></p></td><td style="width:127px"><p>45<sup>&sect;</sup></p></td><td style="width:123px"><p>29</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td style="width:120px"><p>&nbsp;</p></td><td style="width:127px"><p>&nbsp;</p></td><td style="width:123px"><p>&nbsp;</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td style="width:120px"><p>&minus;2.7</p></td><td style="width:127px"><p>&minus;3.2</p></td><td style="width:123px"><p>&minus;1.0</p></td></tr><tr><td><p>Difference from sitagliptin<sup>1</sup> [95% CI]</p></td><td style="width:120px"><p>&minus;1.7 [&minus;2.3; &minus;1.0]<sup>&sect;</sup></p></td><td style="width:127px"><p>&minus;2.1 [&minus;2.8; &minus;1.5]<sup>&sect;</sup></p></td><td style="width:123px"><p>-</p></td></tr></tbody></table><p><sup>1</sup> Irrespective of treatment discontinuation or initiation of rescue medication (pattern mixture model using multiple imputation). <sup>* </sup>p&lt;0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. <sup>&sect;</sup> p&lt;0.05, not controlled for multiplicity; for &lsquo;Patients achieving HbA<sub>1c</sub> &lt;7.0%&rsquo;, the p-value is for the odds ratio.</p><p>&nbsp;</p><p><em><u>PIONEER 4 &ndash; Semaglutide vs. liraglutide and placebo, all in combination with metformin or</u> <u>metformin with an SGLT2 inhibitor</u> </em></p><p>In a 52-week double-blind, double-dummy trial, 711 patients with type 2 diabetes were randomised to semaglutide 14 mg, liraglutide 1.8 mg s.c. injection or placebo once daily, all in combination with metformin or metformin and an SGLT2 inhibitor.</p><p>&nbsp;</p><p>Table 5 Results of a 52-week trial comparing semaglutide with liraglutide and placebo (PIONEER 4)&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Semaglutide</strong><strong> </strong><strong>14 mg</strong></p></td><td><p><strong>Liraglutide</strong></p><p><strong>1.8 mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>285</p></td><td><p>284</p></td><td><p>142</p></td></tr><tr><td><p><strong>Week 26</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>8.0</p></td><td><p>8.0</p></td><td><p>7.9</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.2</p></td><td><p>&minus;1.1</p></td><td><p>&minus;0.2</p></td></tr><tr><td><p>Difference from liraglutide<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.1 [&minus;0.3; 0.0]</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.1 [&minus;1.2; &minus;0.9]*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>68&sect;,a</p></td><td><p>62</p></td><td><p>14</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>9.3</p></td><td><p>9.3</p></td><td><p>9.2</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;2.0</p></td><td><p>&minus;1.9</p></td><td><p>&minus;0.4</p></td></tr><tr><td><p>Difference from liraglutide<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.1 [&minus;0.4; 0.1]</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.6 [&minus;2.0; &minus;1.3]<sup>&sect;</sup></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>92.9</p></td><td><p>95.5</p></td><td><p>93.2</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;4.4</p></td><td><p>&minus;3.1</p></td><td><p>&minus;0.5</p></td></tr><tr><td><p>Difference from liraglutide<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.2 [&minus;1.9; &minus;0.6]*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;3.8 [&minus;4.7; &minus;3.0]*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p><strong>Week 52</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.2</p></td><td><p>&minus;0.9</p></td><td><p>&minus;0.2</p></td></tr><tr><td><p>Difference from liraglutide<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.3 [&minus;0.5; &minus;0.1]<sup>&sect;</sup></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.0 [&minus;1.2; &minus;0.8]<sup>&sect;</sup></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>61&sect;,a</p></td><td><p>55</p></td><td><p>15</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;4.3</p></td><td><p>&minus;3.0</p></td><td><p>&minus;1.0</p></td></tr><tr><td><p>Difference from liraglutide<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.3 [&minus;2.1; &minus;0.5]<sup>&sect;</sup></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;3.3 [&minus;4.3; &minus;2.4]<sup>&sect;</sup></p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p><sup>1</sup> Irrespective of treatment discontinuation or initiation of rescue medication (pattern mixture model using multiple imputation). <sup>* </sup>p&lt;0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. <sup>&sect;</sup> p&lt;0.05, not controlled for multiplicity; for &lsquo;Patients achieving HbA<sub>1c</sub> &lt;7.0%&rsquo;, the p-value is for the odds ratio. <sup>a</sup> vs placebo.</p><p>&nbsp;</p><p><em><u>PIONEER 5 &ndash; Semaglutide vs. placebo, both in combination with basal insulin alone, metformin and</u> <u>basal insulin or metformin and/or sulfonylurea, in patients with moderate renal impairment</u> </em>In a 26-week double-blind trial, 324 patients with type 2 diabetes and moderate renal impairment (eGFR 30-59 ml/min/1.73 m<sup>2</sup>) were randomised to semaglutide 14 mg or placebo once daily. Trial product was added to the patient&rsquo;s stable pre-trial antidiabetic regimen.</p><p>&nbsp;</p><p>Table 6 Results of a 26-week trial comparing semaglutide with placebo in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) &nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Semaglutide 14 mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>163</p></td><td><p>161</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>8.0</p></td><td><p>7.9</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.0</p></td><td><p>&minus;0.2</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.8 [&minus;1.0; &minus;0.6]<sup>*</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>58<sup>&sect;</sup></p></td><td><p>23</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>9.1</p></td><td><p>9.1</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.5</p></td><td><p>&minus;0.4</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.2 [&minus;1.7; &minus;0.6]<sup>&sect;</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>91.3</p></td><td><p>90.4</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;3.4</p></td><td><p>&minus;0.9</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;2.5 [&minus;3.2; &minus;1.8]<sup>*</sup></p></td><td><p>-</p></td></tr></tbody></table><p><sup>1</sup> Irrespective of treatment discontinuation or initiation of rescue medication (pattern mixture model using multiple imputation).<sup> * </sup>p&lt;0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. <sup>&sect;</sup> p&lt;0.05, not controlled for multiplicity; for &lsquo;Patients achieving HbA<sub>1c</sub> &lt;7.0%&rsquo;, the p-value is for the odds ratio.</p><p>&nbsp;</p><p><em><u>PIONEER 7 &ndash; Semaglutide vs. sitagliptin, both in combination with metformin, SGLT2 inhibitors,</u> <u>sulfonylurea or thiazolidinediones. Flexible-dose-adjustment trial</u>&nbsp; </em></p><p>In a 52-week open-label trial, 504 patients with type 2 diabetes were randomised to semaglutide (flexible dose adjustment of 3 mg, 7 mg, and 14 mg once daily) or sitagliptin 100 mg once daily, all in combination with 1-2 oral glucose-lowering medicinal products (metformin, SGLT2 inhibitors, sulfonylurea or thiazolidinediones). The dose of semaglutide was adjusted every 8 weeks based on patient&rsquo;s glycaemic response and tolerability. The sitagliptin 100 mg dose was fixed. The efficacy and safety of semaglutide were evaluated at week 52.</p><p>&nbsp;</p><p>At week 52, the proportion of patients on treatment with semaglutide 3 mg, 7 mg and 14 mg was approximately 10%, 30% and 60%, respectively.</p><p>&nbsp;</p><p>Table 7 Results of a 52-week flexible-dose-adjustment trial comparing semaglutide with sitagliptin (PIONEER 7) &nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Semaglutide Flexible dose</strong></p></td><td><p><strong>Sitagliptin</strong><strong> </strong><strong>100 mg</strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>253</p></td><td><p>251</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>8.3</p></td><td><p>8.3</p></td></tr><tr><td><p>Patients (%) achieving HbA<sub>1c</sub> &lt;7.0%<sup>1</sup></p></td><td><p>58*</p></td><td><p>25</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>88.9</p></td><td><p>88.4</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;2.6</p></td><td><p>&minus;0.7</p></td></tr><tr><td><p>Difference from sitagliptin<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.9 [&minus;2.6; &minus;1.2]*</p></td><td><p>-</p></td></tr></tbody></table><p><sup>1</sup> Irrespective of treatment discontinuation (16.6% of the patients with semaglutide flexible dose and 9.2% with sitagliptin, where 8.7% and 4.0%, respectively, were due to AEs) or initiation of rescue medication (pattern mixture model using multiple imputation). <sup>* </sup>p&lt;0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity (for &lsquo;Patients achieving HbA<sub>1c</sub> &lt;7.0%&rsquo;, the p-value is for the odds ratio).</p><p>&nbsp;</p><p><em><u>PIONEER 8 &ndash; Semaglutide vs. placebo, both in combination with insulin with or without metformin</u> </em></p><p>In a 52-week double-blind trial, 731 patients with type 2 diabetes inadequately controlled on insulin (basal, basal/bolus or premixed) with or without metformin were randomised to semaglutide 3 mg, semaglutide 7 mg, semaglutide 14 mg or placebo once daily.</p><p>&nbsp;</p><p>Table 8 Results of a 52-week trial comparing semaglutide with placebo in combination with insulin (PIONEER 8) &nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Semaglutide</strong><strong> </strong><strong>7 mg</strong></p></td><td><p><strong>Semaglutide</strong><strong> </strong><strong>14 mg</strong></p></td><td><p><strong>Placebo</strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>182</p></td><td><p>181</p></td><td><p>184</p></td></tr><tr><td><p><strong>Week 26 (insulin dose capped to baseline level)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>8.2</p></td><td><p>8.2</p></td><td><p>8.2</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;0.9</p></td><td><p>&minus;1.3</p></td><td><p>&minus;0.1</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.9 [&minus;1.1; &minus;0.7]*</p></td><td><p>&minus;1.2 [&minus;1.4; &minus;1.0]*</p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>43<sup>&sect;</sup></p></td><td><p>58<sup>&sect;</sup></p></td><td><p>7</p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>8.5</p></td><td><p>8.3</p></td><td><p>8.3</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;1.1</p></td><td><p>&minus;1.3</p></td><td><p>0.3</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;1.4 [&minus;1.9; &minus;0.8]<sup>&sect;</sup></p></td><td><p>&minus;1.6 [&minus;2.2; &minus;1.1]<sup>&sect;</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Baseline</p></td><td><p>87.1</p></td><td><p>84.6</p></td><td><p>86.0</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;2.4</p></td><td><p>&minus;3.7</p></td><td><p>&minus;0.4</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;2.0 [&minus;3.0; &minus;1.0]*</p></td><td><p>&minus;3.3 [&minus;4.2; &minus;2.3]*</p></td><td><p>-</p></td></tr><tr><td><p><strong>Week 52 (uncapped insulin dose)<sup>+</sup></strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>HbA</strong><strong>1c </strong><strong>(%)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;0.8</p></td><td><p>&minus;1.2</p></td><td><p>-0.2</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;0.6 [&minus;0.8; &minus;0.4]<sup>&sect;</sup></p></td><td><p>&minus;0.9 [&minus;1.1; &minus;0.7]<sup>&sect;</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>Patients (%) achieving HbA</strong><strong>1c </strong><strong>&lt;7.0%</strong></p></td><td><p>40<sup>&sect;</sup></p></td><td><p>54<sup>&sect;</sup></p></td><td><p>9</p></td></tr><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Change from baseline<sup>1</sup></p></td><td><p>&minus;2.0</p></td><td><p>&minus;3.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>&minus;2.5 [&minus;3.6; &minus;1.4]<sup>&sect;</sup></p></td><td><p>&minus;4.3 [&minus;5.3; &minus;3.2]<sup>&sect;</sup></p></td><td><p>-</p></td></tr></tbody></table><p>[1] Irrespective of treatment discontinuation or initiation of rescue medication (pattern mixture model using multiple imputation). <sup>* </sup>p&lt;0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity.<sup> &sect;</sup> p&lt;0.05, not controlled for multiplicity; for &lsquo;Patients achieving HbA<sub>1c</sub> &lt;7.0%&rsquo;, the p-value is for the odds ratio. <sup>+</sup> The total daily insulin dose was statistically significantly lower with semaglutide than with placebo at week 52. .</p><p>&nbsp;</p><p>Cardiovascular evaluation</p><p>&nbsp;</p><p>In a double-blind trial (PIONEER 6), 3,183 patients with type 2 diabetes at high cardiovascular risk were randomised to Rybelsus 14 mg once daily or placebo in addition to standard-of-care. The median observation period was 16 months.&nbsp;</p><p>&nbsp;</p><p>The primary endpoint was time from randomisation to first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.</p><p>&nbsp;</p><p>Patients eligible to enter the trial were: 50 years of age or older and with established cardiovascular disease and/or chronic kidney disease, or 60 years of age or older and with cardiovascular risk factors only. In total, 1,797 patients (56.5%) had established cardiovascular disease without chronic kidney disease, 354 (11.1%) had chronic kidney disease only and 544 (17.1%) had both cardiovascular disease and kidney disease. 488 patients (15.3%) had cardiovascular risk factors only. The mean age at baseline was 66 years, and 68% of the patients were men. The mean duration of diabetes was 14.9 years and the mean BMI was 32.3 kg/m<sup>2</sup>. Medical history included stroke (11.7%) and myocardial infarction (36.1%).</p><p>&nbsp;</p><p>The total number of first MACE was 137: 61 (3.8%) with semaglutide and 76 (4.8%) with placebo. The analysis of time to first MACE resulted in a HR of 0.79 [0.57; 1.11]<sub>95% CI</sub>.</p><p><img alt="" width="649" height="440" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Cumulative incidence plot of primary outcome (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) with non-cardiovascular death as competing risk.&nbsp;</p><p>Abbreviations: CI: Confidence interval, HR: Hazard ratio</p><p><strong>Figure 1 Cumulative incidence of first occurrence of MACE in PIONEER 6&nbsp; </strong></p><p><img alt="" width="708" height="502" src="data:image/png;base64,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" /></p><p><strong>Figure 2 Treatment effect for the primary composite endpoint, its components and all cause death (PIONEER 6)&nbsp; </strong></p><p>&nbsp;</p><p>Body weight</p><p>&nbsp;</p><p>By end-of-treatment, 27-45% of the patients had achieved a weight loss of &ge;5% and 6-16% had achieved a weight loss of &ge;10% with semaglutide, compared with 12-39% and 2-8%, respectively, with the active comparators.&nbsp;</p><p>&nbsp;</p><p><u>Blood pressure</u></p><p>&nbsp;</p><p>Treatment with semaglutide had reduced systolic blood pressure by 2-7 mmHg.</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Rybelsus in one or more subsets of the paediatric population in type 2 diabetes (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Orally administered semaglutide has a low absolute bioavailability and a variable absorption. Daily administration according to the recommended posology in combination with a long half-life reduces day-to-day fluctuation of the exposure.</p><p>&nbsp;</p><p>The pharmacokinetics of semaglutide have been extensively characterised in healthy subjects and patients with type 2 diabetes. Following oral administration, maximum plasma concentration of semaglutide occurred 1 hour post dose. Steady-state exposure was reached after 4&ndash;5 weeks of once-daily administration. In patients with type 2 diabetes, the average steady-state concentrations were approximately 6.7&nbsp;nmol/L and 14.6&nbsp;nmol/L with semaglutide 7&nbsp;mg and 14&nbsp;mg, respectively; with 90% of subjects treated with semaglutide 7&nbsp;mg having an average concentration between 1.7 and 22.7&nbsp;nmol/L and 90% of subjects treated with semaglutide 14&nbsp;mg having an average concentration between 3.7 and 41.3&nbsp;nmol/L. Systemic exposure of semaglutide increased in a dose-proportional manner.</p><p>&nbsp;</p><p>Based on <em>in vitro</em> data, salcaprozate sodium facilitates absorption of semaglutide. The absorption of semaglutide predominantly occurs in the stomach.</p><p>&nbsp;</p><p>The estimated bioavailability of semaglutide is approximately 1% following oral administration. The between-subject variability in absorption was high (coefficient of variation was approximately 100%). The estimation of the within-subject variability in bioavailability was not reliable.</p><p>&nbsp;</p><p>Absorption of semaglutide is decreased if taken with food or large volumes of water. A longer post-dose fasting period results in higher absorption.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The estimated absolute volume of distribution is approximately 8&nbsp;L in subjects with type 2 diabetes. Semaglutide is extensively bound to plasma proteins (&gt;99%).</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Semaglutide is metabolised through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid sidechain. The enzyme neutral endopeptidase (NEP) is expected to be involved in the metabolism of semaglutide.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>The primary excretion routes of semaglutide-related material are via the urine and faeces. Approximately 3% of the absorbed dose is excreted as intact semaglutide via the urine.</p><p>&nbsp;</p><p>With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last dose. The clearance of semaglutide in patients with type 2 diabetes is approximately 0.04&nbsp;L/h.</p><p>&nbsp;</p><p><u>Switching between oral and subcutaneous (s.c.) administration</u></p><p><u>&nbsp;</u></p><p>The effect of switching between oral and s.c. semaglutide cannot easily be predicted because of the high pharmacokinetic variability of oral semaglutide. Exposure after oral semaglutide 14 mg once daily is comparable to s.c. semaglutide 0.5 mg once weekly. An oral dose equivalent to 1.0 mg of s.c. semaglutide has not been established.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>Age had no effect on the pharmacokinetics of semaglutide based on data from clinical trials, which studied patients up to 92&nbsp;years of age.</p><p>&nbsp;</p><p><em>Gender</em></p><p>Gender had no clinically meaningful effects on the pharmacokinetics of semaglutide.</p><p>&nbsp;</p><p><em>Race and ethnicity</em></p><p>Race (White, Black or African-American, Asian) and ethnicity (Hispanic or Latino, not Hispanic or Latino) had no effect on the pharmacokinetics of semaglutide.</p><p>&nbsp;</p><p><em>Body weight</em></p><p>Body weight had an effect on the exposure of semaglutide. Higher body weight was associated with lower exposure. Semaglutide provided adequate systemic exposure over the body weight range of 40‑188&nbsp;kg evaluated in the clinical trials.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Renal impairment did not impact the pharmacokinetics of semaglutide in a clinically relevant manner. The pharmacokinetics of semaglutide were evaluated in patients with mild, moderate or severe renal impairment and patients with end-stage renal disease on dialysis compared with subjects with normal renal function in a study with 10 consecutive days of once-daily doses of semaglutide. This was also shown for subjects with type 2 diabetes and renal impairment based on data from phase 3a studies.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>Hepatic impairment did not impact the pharmacokinetics of semaglutide in a clinically relevant manner. The pharmacokinetics of semaglutide were evaluated in patients with mild, moderate or severe hepatic impairment compared with subjects with normal hepatic function in a study with 10 consecutive days of once-daily doses of semaglutide.</p><p>&nbsp;</p><p><em>Upper GI tract disease</em></p><p>Upper GI tract disease (chronic gastritis and/or gastroesophageal reflux disease) did not impact the pharmacokinetics of semaglutide in a clinically relevant manner. The pharmacokinetics were evaluated in patients with type 2 diabetes with or without upper GI tract disease dosed for 10 consecutive days with once-daily doses of semaglutide. This was also shown for subjects with type 2 diabetes and upper GI tract disease based on data from phase 3a studies.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Semaglutide has not been studied in paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity or genotoxicity.</p><p>&nbsp;</p><p>Non-lethal thyroid C-cell tumours observed in rodents are a class effect for GLP‑1 receptor agonists. In 2-year carcinogenicity studies in rats and mice, semaglutide caused thyroid C-cell tumours at clinically relevant exposures. No other treatment-related tumours were observed. The rodent C-cell tumours are caused by a non-genotoxic, specific GLP‑1 receptor mediated mechanism to which rodents are particularly sensitive. The relevance for humans is considered to be low, but cannot be completely excluded.</p><p>&nbsp;</p><p>In fertility studies in rats, semaglutide did not affect mating performance or male fertility. In female rats, an increase in oestrous cycle length and a small reduction in <em>corpora lutea</em> (ovulations) were observed at doses associated with maternal body weight loss.</p><p>&nbsp;</p><p>In embryo-foetal development studies in rats, semaglutide caused embryotoxicity below clinically relevant exposures. Semaglutide caused marked reductions in maternal body weight and reductions in embryonic survival and growth. In foetuses, major skeletal and visceral malformations were observed, including effects on long bones, ribs, vertebrae, tail, blood vessels and brain ventricles. Mechanistic evaluations indicated that the embryotoxicity involved a GLP‑1 receptor mediated impairment of the nutrient supply to the embryo across the rat yolk sac. Due to species differences in yolk sac anatomy and function, and due to the lack of GLP‑1 receptor expression in the yolk sac of non-human primates, this mechanism is considered unlikely to be of relevance to humans. However, a direct effect of semaglutide on the foetus cannot be excluded.</p><p>&nbsp;</p><p>In developmental toxicity studies in rabbits and cynomolgus monkeys, increased pregnancy loss and slightly increased incidence of foetal abnormalities were observed at clinically relevant exposures. The findings coincided with marked maternal body weight loss of up to 16%. Whether these effects are related to the decreased maternal food consumption as a direct GLP‑1 effect is unknown.</p><p>&nbsp;</p><p>Postnatal growth and development were evaluated in cynomolgus monkeys. Infants were slightly smaller at delivery, but recovered during the lactation period.</p><p>&nbsp;</p><p>In juvenile rats, semaglutide caused delayed sexual maturation in both males and females. These delays had no impact upon fertility and reproductive capacity of either sex, or on the ability of the females to maintain pregnancy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Salcaprozate sodium</p><p>Povidone K90</p><p>Cellulose, microcrystalline</p><p>Magnesium stearate</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
3 mg: 24 months
7 mg: 30 months
14 mg: 30 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original blister package in order to protect from light and moisture. This medicinal product does not require any special temperature storage conditions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/Alu blisters.</p><p>Pack sizes of 3 mg tablets: 10, 30, 60, 90 and 100 tablets.</p><p>Pack sizes of 7 mg tablets: 10, 30, 60, 90 and 100 tablets.</p><p>Pack sizes of 14 mg tablets: 10, 30, 60, 90 and 100 tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>